✦ LIBER ✦

PHARMACOLOGIC STUDY OF 3-HOUR 135 mg m−2PACLITAXEL IN PLATINUM PRETREATED PATIENTS WITH ADVANCED OVARIAN CANCER

✍ Scribed by VINODH R.NANNAN PANDAY; MANON T. HUIZING; LAURENCE J.C. van WARMERDAM; RIA C. DUBBELMAN; INGRID MANDJES; JAN H.M. SCHELLENS; WIM W.TEN BOKKEL HUININK; JOS H. BEIJNEN

Book ID: 118770563
Publisher: Elsevier Science
Year: 1998
Tongue: English
Weight: 101 KB
Volume: 38
Category: Article
ISSN: 1043-6618
DOI: 10.1006/phrs.1998.0360

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

507 A phase II study of taxol® (T) (pacl

507 A phase II study of taxol® (T) (paclitaxel) over 3 hours (H) in 192 platinum pretreated patients (PTS) for ovarian carcinoma (OC)

✍ C. Lhommé; J.P. Guastalla; J. Dauplat; J.M. Ferrero; F. Oberling; P. Vennin; P. 📂 Article 📅 1995 🏛 Elsevier Science 🌐 English ⚖ 163 KB

Phase II trial of weekly paclitaxel (80

Phase II trial of weekly paclitaxel (80 mg/m2) in platinum and paclitaxel-resistant ovarian and primary peritoneal cancers: A Gynecologic Oncology Group study

✍ Maurie Markman; John Blessing; Stephen C. Rubin; Joseph Connor; Parviz Hanjani; 📂 Article 📅 2006 🏛 Elsevier Science 🌐 English ⚖ 97 KB

Phase I/II study of oral etoposide plus

Phase I/II study of oral etoposide plus GM-CSF as second-line chemotherapy in platinum-pretreated patients with advanced ovarian cancer

✍ Baur, M; Schernhammer, E; Gneist, M; Sevelda, P; Speiser, P; Hudec, M; Dittrich, 📂 Article 📅 2005 🏛 Nature Publishing Group 🌐 English ⚖ 109 KB

Extended phase II study of paclitaxel as

Extended phase II study of paclitaxel as a 3-h infusion in patients with ovarian cancer previously treated with platinum

✍ A. du Bois; H.J. Lück; K. Buser; H.G. Meerpohl; C. Sessa; U. Klaassen; H. Meden; 📂 Article 📅 1997 🏛 Elsevier Science 🌐 English ⚖ 693 KB

Phase 2 Study of TLK286 (GST P1-1 Activa

Phase 2 Study of TLK286 (GST P1-1 Activated Glutathione Analog) in patients with platinum and paclitaxel refractory/resistant advanced epithelial ovarian cancer

📂 Article 📅 2002 🏛 Elsevier Science 🌐 English ⚖ 265 KB

Impact on survival of 12 versus 3 monthl

Impact on survival of 12 versus 3 monthly cycles of paclitaxel (175 mg/m2) administered to patients with advanced ovarian cancer who attained a complete response to primary platinum-paclitaxel: Follow-up of a Southwest Oncology Group and Gynecologic Oncology Group phase 3 trial

✍ Maurie Markman; P.Y. Liu; James Moon; Bradley J. Monk; Larry Copeland; Sharon Wi 📂 Article 📅 2009 🏛 Elsevier Science 🌐 English ⚖ 307 KB